CRIS Current Research Information System

MASSARI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.909
NA - Nord America 7.413
EU - Europa 4.677
SA - Sud America 1.204
AF - Africa 610
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 6
Totale 29.835
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.249
SG - Singapore 4.678
CN - Cina 4.271
VN - Vietnam 3.278
HK - Hong Kong 1.375
IT - Italia 1.251
BR - Brasile 921
KR - Corea 840
GB - Regno Unito 532
IN - India 469
DE - Germania 467
SE - Svezia 423
NL - Olanda 380
FR - Francia 360
FI - Finlandia 254
RU - Federazione Russa 217
CH - Svizzera 216
JP - Giappone 210
SC - Seychelles 199
IE - Irlanda 166
CI - Costa d'Avorio 131
AR - Argentina 125
ZA - Sudafrica 121
ID - Indonesia 102
PH - Filippine 102
BD - Bangladesh 83
CA - Canada 75
AT - Austria 74
TH - Thailandia 68
TR - Turchia 65
IQ - Iraq 63
BG - Bulgaria 59
MX - Messico 56
JO - Giordania 49
TG - Togo 49
PK - Pakistan 46
PL - Polonia 46
UA - Ucraina 45
TW - Taiwan 42
ES - Italia 41
EC - Ecuador 37
EE - Estonia 30
VE - Venezuela 30
BE - Belgio 28
CO - Colombia 26
SA - Arabia Saudita 26
CL - Cile 23
MY - Malesia 23
UZ - Uzbekistan 23
KE - Kenya 17
AU - Australia 15
NG - Nigeria 15
PY - Paraguay 15
UY - Uruguay 15
EG - Egitto 14
LT - Lituania 14
AZ - Azerbaigian 13
IL - Israele 12
TN - Tunisia 12
PE - Perù 11
PT - Portogallo 11
MA - Marocco 10
GR - Grecia 9
HR - Croazia 9
LB - Libano 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
DZ - Algeria 8
NP - Nepal 8
JM - Giamaica 7
KZ - Kazakistan 7
OM - Oman 6
PS - Palestinian Territory 6
RO - Romania 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
IR - Iran 5
KG - Kirghizistan 5
SN - Senegal 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
HN - Honduras 4
HU - Ungheria 4
XK - ???statistics.table.value.countryCode.XK??? 4
CD - Congo 3
CR - Costa Rica 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GH - Ghana 3
LV - Lettonia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
GD - Grenada 2
IS - Islanda 2
KW - Kuwait 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
ML - Mali 2
Totale 29.797
Salva come PNG Salva come JPEG
Città #
Singapore 3.152
Hefei 1.770
Hong Kong 1.307
Ashburn 872
Ho Chi Minh City 852
Seoul 800
Hanoi 758
San Jose 578
Boardman 486
Santa Clara 407
Fairfield 374
Southend 355
Beijing 353
Chandler 311
Council Bluffs 255
Los Angeles 252
Bologna 250
Bern 207
Lauterbourg 191
Helsinki 188
Seattle 180
Bengaluru 166
Tokyo 165
Dublin 164
Wilmington 161
Woodbridge 160
Houston 146
Milan 141
Abidjan 131
Cambridge 129
Da Nang 129
Princeton 127
Dallas 123
Dong Ket 122
Buffalo 119
Redondo Beach 107
New York 100
São Paulo 90
Haiphong 85
Guangzhou 78
Boydton 73
Nuremberg 71
Ann Arbor 69
Shanghai 68
Frankfurt am Main 65
Johannesburg 64
Jakarta 62
Rome 59
Turin 57
Lappeenranta 56
Sofia 55
Tongling 54
Chicago 50
Amsterdam 49
Lomé 49
Amman 48
Castel Maggiore 46
Nanjing 46
Hải Dương 43
Biên Hòa 41
Vienna 40
Westminster 37
Florence 36
Redmond 36
Can Tho 35
Berlin 33
Quận Bình Thạnh 33
Changsha 32
Munich 32
Falkenstein 30
Ninh Bình 30
Rio de Janeiro 30
Thái Nguyên 29
Warsaw 29
Jinan 28
Montreal 28
Shenzhen 28
Ha Long 27
Hyderabad 27
London 26
Paris 26
Tianjin 26
Brussels 25
San Diego 25
Zhengzhou 25
Padova 24
Redwood City 24
Xi'an 24
Bắc Ninh 23
Orem 23
Long Xuyen 22
Salt Lake City 22
Yubileyny 22
Baghdad 21
Bangkok 21
Boston 21
Denver 21
Hangzhou 21
Phoenix 21
Shenyang 21
Totale 18.550
Salva come PNG Salva come JPEG
Nome #
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 264
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 254
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 248
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 228
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 215
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 213
Circulating tumor cells in genitourinary tumors 213
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 199
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 193
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 184
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 184
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. 182
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial 178
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 175
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 174
Sopravvivenza di pazienti con recidiva vaginale di carcinoma endometriale: il ruolo della radioterapia e della chirurgia. 170
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 169
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. 167
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 165
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 165
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 160
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 160
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 160
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 159
Bone targeting agents in patients with metastatic prostate cancer: State of the art 157
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 157
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 156
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation 155
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 155
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 155
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 155
Immune checkpoint inhibitors for metastatic bladder cancer 153
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience 150
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 149
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 149
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 148
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 148
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? 148
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 148
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 147
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 147
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 147
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 145
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 144
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 144
The human microbiota and prostate cancer: Friend or foe? 143
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 141
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 140
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 139
Expected and non-expected immune-related adverse events detectable by CT 139
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 138
Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice 137
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 137
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 136
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 136
Is There a Role for Immunotherapy in Prostate Cancer? 135
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 134
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 134
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives 133
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 133
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 132
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 131
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 131
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study 130
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: Where do we stand? 130
Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis 130
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 129
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 129
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer 128
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 127
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 126
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 126
BAP1 in solid tumors 124
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 123
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 123
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 121
Urinary biomarkers for prostate cancer 121
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 120
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 120
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis 119
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab 118
Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer 118
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 118
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 118
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 117
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 117
The prospect of precision therapy for renal cell carcinoma. 117
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 116
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 113
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 112
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 112
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 111
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance 110
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 110
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 108
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 108
Totale 14.750
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.629
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021414 0 0 0 0 0 0 0 0 0 44 29 341
2021/20221.091 46 33 41 81 88 56 41 101 133 47 282 142
2022/20232.575 112 151 59 169 214 460 212 129 388 70 228 383
2023/20241.133 131 171 94 95 84 140 37 93 56 91 73 68
2024/20257.012 209 688 728 406 851 255 453 209 224 428 828 1.733
2025/202616.742 2.136 2.466 2.287 1.684 1.516 644 1.566 604 2.715 1.124 0 0
Totale 30.758